» Articles » PMID: 35704239

Elevation of Major Constitutive Heat Shock Proteins is Heat Shock Factor Independent and Essential for Establishment and Growth of Lgl Loss and Yorkie Gain-mediated Tumors in Drosophila

Overview
Publisher Elsevier
Specialty Cell Biology
Date 2022 Jun 15
PMID 35704239
Authors
Affiliations
Soon will be listed here.
Abstract

Cancer cells generally overexpress heat shock proteins (Hsps), the major components of cellular stress response, to overcome and survive the diverse stresses. However, the specific roles of Hsps in initiation and establishment of cancers remain unclear. Using loss of Lgl-mediated epithelial tumorigenesis in Drosophila, we induced tumorigenic somatic clones of different genetic backgrounds to examine the temporal and spatial expression and roles of major heat shock proteins in tumor growth. The constitutively expressed Hsp83, Hsc70 (heat shock cognate), Hsp60 and Hsp27 show elevated levels in all cells of the tumorigenic clone since early stages, which persists till their transformation. However, the stress-inducible Hsp70 is expressd only in a few cells at later stage of established tumorous clones that show high F-actin aggregation. Intriguingly, levels of heat shock factor (HSF), the master regulator of Hsps, remain unaltered in these tumorous cells and its down-regulation does not affect tumorigenic growth of lgl clones overexpressing Yorkie, although down-regulation of Hsp83 prevents their survival and growth. Interestingly, overexpression of HSF or Hsp83 in lgl cells makes them competitively successful in establishing tumorous clones. These results show that the major constitutively expressed Hsps, but not the stress-inducible Hsp70, are involved in early as well as late stages of epithelial tumors and their elevated expression in lgl clones co-overexpressing Yorkie is independent of HSF.

Citing Articles

Hsc70-4 aggravates PolyQ-mediated neurodegeneration by modulating NF-κB mediated immune response in .

Rai S, Tapadia M Front Mol Neurosci. 2022; 15:857257.

PMID: 36425218 PMC: 9678916. DOI: 10.3389/fnmol.2022.857257.

References
1.
Aswad A, Liu T . Targeting heat shock protein 90 for anti-cancer drug development. Adv Cancer Res. 2021; 152:179-204. DOI: 10.1016/bs.acr.2021.03.006. View

2.
Yokota J . Tumor progression and metastasis. Carcinogenesis. 2000; 21(3):497-503. DOI: 10.1093/carcin/21.3.497. View

3.
Chatterjee S, Burns T . Targeting Heat Shock Proteins in Cancer: A Promising Therapeutic Approach. Int J Mol Sci. 2017; 18(9). PMC: 5618627. DOI: 10.3390/ijms18091978. View

4.
Cyran A, Zhitkovich A . Heat Shock Proteins and HSF1 in Cancer. Front Oncol. 2022; 12:860320. PMC: 8924369. DOI: 10.3389/fonc.2022.860320. View

5.
Vogelstein B, Fearon E, Hamilton S, Kern S, Preisinger A, Leppert M . Genetic alterations during colorectal-tumor development. N Engl J Med. 1988; 319(9):525-32. DOI: 10.1056/NEJM198809013190901. View